Neoantigen vaccines aim to train the immune system to recognize and attack cancer cells by introducing these unique neoantigens. The process involves identifying patient-specific mutations through genomic sequencing, predicting which mutated peptides will bind to major histocompatibility complex (MHC) molecules, and then synthesizing these peptides to create a personalized vaccine.
